PNL21 INDEPENDENT EFFECT OF DYSKINESIA ON HEALTHRELATED QUALITY OF LIFE IN PATIENTS WITH PARKINSON'S DISEASE—A MULTIVARIATE ANALYSIS  by Siebert, U et al.
793Abstracts
Patients previously diagnosed, suffering from a psychotic disor-
der or unable to follow-up the study were excluded. Three visits
were conducted per protocol (baseline, 6 and 12 months).
RESULTS: A total of 921 patients were included in the analysis.
Mean (SD) age was 74.3 (6.8) years and 66.9% were women.
First suspected diagnosis were: age related memory impairment
(17.5% of patients), cognitive impairment (21.9%), dementia
(29.2%), and psychopathological disorders (14.9%). Diagnostic
methods used were: anamnesis (96,2% of patients); physical and
neurological examination (87,5% and 85.6%), screening and
laboratory test (85.9% and 89%). In all, 630 patients attended
to at least one visit “out of protocol” to their PCP during the
follow-up period. Mean (SD) number of visits was 4.28 (3.1).
Percentile 25, 50, and 75 were 2, 3, and 6 visits respectively. The
visits were previously appointed by physicians (54.7%) or were
patients spontaneous consultations (39.7%). Main reason for
“out of protocol” visits were to evaluate patient evolution.
45.1% of patients were never derived, 36.9% and 18% were
derived to specialist once, or more than once, respectively. Main
reason was diagnostic conﬁrmation. CONCLUSION: Initial visit
of patients with memory complaints or cognitive impairment to
PCP, originate a careful follow-up of the patient. Different
number of diagnostic methods and high time consumer proce-
dures (as anamnesis, or screening test) have been applied. Deriva-
tions to specialist seem to be low.
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OBJECTIVES: To determine the psychometric properties of the
RLSQoL (V1.1) in a clinical trial setting. METHODS: Patient
populations from two matching, placebo-controlled, multina-
tional studies assessing the effectiveness and safety of ropinirole
for treating moderate-to-severe RLS formed the basis of a psy-
chometric assessment of the RLSQoL. Tests for validity and reli-
ability were performed using baseline data. Responsiveness was
determined using longitudinal, 12-week data. Tests were per-
formed on blinded, individual trial data. RESULTS: A total of
547 subjects formed the baseline validation population, 519
were used for assessing responsiveness (n = 284/271 and 263/248
for both studies, respectively). Construct validity assessment con-
ﬁrmed an overall life-impact score could be calculated (account-
ing for 39% and 46% of the variance in the two studies,
respectively). All items passed the test for item convergent valid-
ity (item-scale correlation ≥0.4), except items 1 “distress” (r =
0.36) and 5 “late for work/ﬁrst appointments” (r = 0.35) in one
study. There were no signiﬁcant missing data, ﬂoor or ceiling
effects for the RLSQoL overall life-impact score. Cronbach’s a
were 0.82 and 0.87, conﬁrming internal consistency reliability of
the scale. Concurrent validity was determined by correlation
with the International Restless Legs Scale, measuring similar
health constructs (r = -0.68, -0.67, p < 0.0001); known groups
validity by its ability to discriminate between subjects with dif-
ferent levels of sleep problems (p < 0.0001) and clinical validity
by its ability to discriminate between levels of global health
status determined by a Clinical Global Impression of severity
(CGI-S) (p < 0.0001). Responsiveness was demonstrated by sta-
tistically signiﬁcant differences in RLSQoL overall life-impact
change scores between CGI improvement levels after 12 weeks
of treatment (p < 0.0001; effect size range: 0.74–1.15 and
0.54–1.51 for improved groups). CONCLUSIONS: The
RLSQoL is a valid, reliable and responsive measure of quality of
life for patients with RLS when used in a clinical trial setting.
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OBJECTIVES: To develop a simple dichotomous scale for the
assessment of RLS severity to be used for facilitating therapeu-
tic decisions. METHODS: A prospective epidemiological study
was conducted in primary healthcare in France. First, patients
fulﬁlling the RLS diagnostic criteria from the International Rest-
less Legs Study Group were identiﬁed. Secondly, severity of iden-
tiﬁed RLS subjects was assessed using the IRLS rating scale. This
scale includes ten items, each rated on a ﬁve point Lickert scale
from zero to four (“non” to “very severe”) and summed in a
global score from zero to 40 (0–20: non-severe; 21–40: severe).
Using a segmentation analysis applied to the rating scale items
and other measures of RLS impact, we attempted to ﬁnd a small
number of items able to distinguish severe from non-severe RLS
patients as the rating scale would have done. RESULTS: A total
of 537 patients were analyzed. Three items came up from the
segmentation analysis, consolidated into “RS-3”. All three were
part of the rating scale. They dealt with: overall RLS severity,
overall sleep disturbance and mood disturbance. The decision
rule was that an answer zero,one or two (ie. none, mild or mod-
erate) to at least one of the three items assigned an RS-3 grade
of “non-severe”. The sensitivity and speciﬁcity of RS-3 were
82% and 95% respectively. The positive and negative predictive
values (PPV and NPV) were 92% and 88%. Sensitivity analyses
with thresholds of 15, 25 and 30 were performed without
improving sensitivity and speciﬁcity. The reproducibility of the
RS-3 was assessed in another RLS population (731 subjects from
the INSTANT Study) with sensitivity / speciﬁcity of 88% and
91%; and PPV and NPV of 73% and 97%, respectively. CON-
CLUSIONS: The metrology of the RS-3 scale appears to be
strong enough to be used in larger sample.
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OBJECTIVES: Dyskinesia is generally thought to severely affect
health-related quality of life (QoL) in patients with Parkinson’s
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disease (PD). We evaluated the independent impact of dyskine-
sia on QoL in patients with PD and evaluated whether com-
monly used QoL instruments are sensitive enough to measure
dyskinesia effects in clinical trials. METHODS: We analyzed
data from the German PD Competence Network comprising
generic (EuroQoL [EQ-5D]) and disease-speciﬁc (PD Question-
naire 39 [PDQ-39]) QoL instruments and clinical variables
including the Uniﬁed Parkinson’s Disease Rating Scale (UPDRS).
We used 4 dyskinesia-speciﬁc UPDRS items (i.e., duration, dis-
ability, painfulness of dyskinesias and presence of early-morning
dystonia) to predict totals and subscores of EQ-5D and PDQ-
39, values of the visual analogue scale (VAS) and EQ-5D derived
utilities. We performed ordinal logistic regression to predict EQ-
5D subscales and multiple linear regression to predict all remain-
ing QoL outcomes. Potential confounders were speciﬁed a priori
by an expert panel and ﬁnal confounders were selected based on
statistical criteria (univariate Spearman’s rank correlation, mul-
tivariate forward selection, p < 0.05). RESULTS: A total of 68
models were investigated (4 dyskinesia ¥ 17 QoL variables), of
which 9 showed a statistically signiﬁcant association after con-
trolling for confounding. The most relevant confounder was
severity of disease. All 4 dyskinesia variables were associated
with at least 1 QoL variable. Dyskinesia duration was shown to
be the most robust predictor. Subscales of EQ-5D and PDQ-39
addressing pain/(bodily) discomfort were associated with all 4
dyskinesia variables. In addition, EQ-5D index was associated
with duration of dyskinesia. CONCLUSIONS: Dyskinesia has a
signiﬁcant impact on QoL measured by EQ-5D and PDQ-39 and
their subscales, even after controlling for confounding. EQ-5D
and PDQ-39 are useful instruments for clinical trials addressing
questions on the effect of potential anti-dyskinesia treatments on
QoL.
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OBJECTIVES: Utility data is often needed in health economic
modeling, but not always available in clinical studies in Parkin-
son’s disease (PD). Therefore, we have recently presented a pre-
diction algorithm to estimate utilities from a clinical rating scale.
We now report effects of major complications in PD on this pre-
diction algorithm. METHODS: Data from an ongoing prospec-
tive cost study of the German Competence Network of
Parkinson Syndromes was used (n = 115). Our prior utility pre-
diction algorithm was exclusively based on subscales II–IV of 
the Uniﬁed Parkinson’s Disease Rating Scale (UPDRS). Now, 
we applied multivariate regression analysis to investigate 
the independent effect of sociodemographic factors (age, sex), 
neuropsychological disturbances (depression, hallucinations,
dementia) and motor complications (falls, dyskinesia, ﬂuctua-
tions) on utilities measured by the EuroQoL (EQ-5D). Depres-
sion was evaluated by Beck’s Depression Inventory (BDI) and
dementia by Mini Mental State Examination. RESULTS: The
study population had a mean age of 67 years and was predom-
inantly male (67%). Mean EQ-5D was 0.74. Among all com-
plications investigated, only depression reached statistical
signiﬁcance (p = 0.03). UPDRS variables (subscores from part II,
III and IV) remained in the model (see equation): EQ-5D =
(103.23 - 1.29*UPDRS II - 0.30*UPDRS III - 1.23*UPDRS 
IV - 0.55*BDI)/100. After adjusting for UPDRS, depression
reduced the utility by 0.55 score units per BDI point. However,
the inclusion of BDI only marginally improved the explained
variance (adjusted R-square increased from 0.51 to 0.52). CON-
CLUSIONS: Whereas sociodemographic factors, motor compli-
cations and neuropsychological disturbances do not exert
independent effects on utilities when controlling for UPDRS,
depression has an independent effect on EQ-5D. Although
depression is not explicitly included in the UPDRS score of parts
II–IV, its inclusion did not substantially reduce the unexplained
variance. It remains to be investigated which factors further
explain the remaining variance.
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OBJECTIVES: The goal of this cross-sectional analysis was to
determine pain impact on Quality of Life (QoL) and interference
with disability among patients with chronic NeP. METHODS:
Participants in an observational, prospective and multicentre
study in Spain (DONEGA study) with NeP of different etiolo-
gies, completed the Short Form-McGill Pain Questionnaire (SF-
MPQ), the MOS Short Form-12 (SF-12), and the Sheehan
Disability Scale at baseline. RESULTS: A total of 1519 patients
[mean ± SD; 56.0 ± 13.7 years old (58.8% female)] with NeP
were enrolled in the study. Patients had NeP for 1.1 ± 2.8 years,
and 83.3% were on any type of analgesic treatment at baseline:
oral analgesics (51.2%), topical analgesics (26.9%), NSAID’s
(11.1%), antiepileptics (7.3%), and psychoanaleptics (3.5%).
Average Pain scores were 13.1 ± 8.2pts., 10.0 ± 5.8pts., and 3.1
± 3.3pts., for total scale (range 0–45), sensory domain (range
0–33), and affective domain (range 0–12), respectively. Present
pain intensity was 2.8 ± 1.0 (range 0–5) and mean pain past week
on a VAS scale was 71.2 ± 18.9mm. Pain substantially interfered
(≥5 on 0–10 scale) with normal work (6.0 ± 3.1), social life (5.7
± 3.0), and family life (5.3 ± 3.0), then producing disability;
Sheehan total (on 0–30 scale): 17.0 ± 8.4pts. Country normal-
ized physical (PCS) and mental health (MCS) component
summary scores (SF-12) indicated signiﬁcant impairment in both
domains compared to the general Spanish population: PCS; 37.6
± 6.0 vs. 50.1 ± 9.5, and MCS; 45.9 ± 8.1 vs. 50.0 ± 9.6, respec-
tively. Increasing levels of refractory pain, as assessed by number
of medications, corresponded to increasing levels of disability
(Sheehan total: 14.2 ± 8.8 to 16.4 ± 8.3, to 18.7 ± 8.1, and to
20.6 ± 7.0, by 0, 1, 2, and 3 medications respectively, p < 0.01
for all between group comparisons except 2 vs. 3). CONCLU-
SIONS: NeP decreases patients’ physical and mental components
of QoL, while increasing level of disability and impaired normal
work. The disability increases with level of pain treatment 
resistance.
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OBJECTIVES: The goal of this cross-sectional evaluation was to
assess pain impact and interference with mental functioning,
